title: Phase II neoadjuvant trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin followed by chest radiotherapy for patients with stage III non-small-cell lung cancer.
abstract: Sixteen patients with untreated locally advanced (n = 15) or recurrent (n = 1) non-small-cell lung cancer (NSCLC) were enrolled in this study between July 1996 and March 1999. Eight patients had stage IIIA NSCLC, seven had stage IIIB disease, and one had recurrent disease after prior resection of stage I disease. Patients were treated with paclitaxel 30 mg/m2/d for 4 days by continuous intravenous infusion followed by cisplatin 80 mg/m2 on day 5. Therapy was administered every 3 weeks until disease progression or a maximum of four cycles. Thoracic radiation was started within 3 to 4 weeks of day 1 of the last cycle of paclitaxel and cisplatin. Fourteen patients (87.5%) received all four cycles of chemotherapy and subsequent radiation therapy. Forty-four percent of patients achieved a partial response, and 1 patient complete response (overall response rate, 50%). The median progression-free survival was 8.8 months. At a median potential follow-up of 3.7 years, the median survival for all 16 enrolled patients was 13.2 months, and the actuarial 1-, 2-, and 3-year survivals were 62.5%, 43.8%, and 21.9%. In contrast to predictions from in vitro cytotoxicity models, the sequential use of prolonged infusional paclitaxel and bolus cisplatin followed by thoracic radiation does not appear to have a greater impact over shorter chemotherapy
authors.affiliation: Medicine Branch, Division of Clinical Sciences, National Cancer Institute (NCI)/National Naval Medical Center, NNMC, Bethesda, Maryland, USA.
authors.forename: O S
authors.initials: OS
authors.lastname: Breathnach
authors.forename: V
authors.initials: V
authors.lastname: Kasturi
authors.forename: F
authors.initials: F
authors.lastname: Kaye
authors.forename: L
authors.initials: L
authors.lastname: Herscher
authors.forename: M S
authors.initials: MS
authors.lastname: Georgiadis
authors.forename: M
authors.initials: M
authors.lastname: Edison
authors.forename: B S
authors.initials: BS
authors.lastname: Schuler
authors.forename: P
authors.initials: P
authors.lastname: Pizzella
authors.forename: S M
authors.initials: SM
authors.lastname: Steinberg
authors.forename: K
authors.initials: K
authors.lastname: O'Neil
authors.forename: Bruce E
authors.initials: BE
authors.lastname: Johnson
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000008:administration & dosage; D011882:Radiotherapy, High-Energy; D016019:Survival Analysis
chemical_list: D017239:Paclitaxel; D002945:Cisplatin